QR Kod

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia

Abstract EVI1-rearranged acute myeloid leukemia (AML) with inv(3)(q21q26) or t(3;3)(q21q26) represents a distinct and aggressive subtype characterized by poor prognosis and limited treatment options. However, the optimal strategy to overcome resistance to conventional therapy remains elusive. Buildi...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Weijia Zang, Yui Koike, Koutarou Nishimura, Atsushi Tanaka, Hiromi Yamazaki, Takaya Yamasaki, Hiromi Ito, Yifan Zhang, Yumi Aoyama, Wataru Saika, Muran Xiao, Chihiro Hasegawa, Hiroyoshi Kunimoto, Hideaki Nakajima, Fumihiko Ishikawa, Akifumi Takaori-Kondo, Daichi Inoue
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Portfolio 2025-10-01
Seri Bilgileri:Scientific Reports
Konular:
Acute myeloid leukemia
EVI1
Venetoclax
Hypomethylating agent
MYB
BRD4
Online Erişim:https://doi.org/10.1038/s41598-025-21034-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller